|
Synonyms: OPS-2071
Compound class:
Synthetic organic
Comment: OPS-2071 is a fluoroquinolone antibacterial compound, with broad-spectrum activity against both Gram-positive and Gram-negative bacteria [2]. It is a clinical candidate being developed by Otsuka Pharmaceutical (Tokyo, Japan) as a treatment for intestinal infections, particularly those caused by Clostridioides difficile. Functionally, it is a type II DNA topoisomerase inhibitor with similar activity against DNA gyrase and DNA topoisomerase 4 [1]. The chemical structure of OPS-2071 is identical to that which was submitted to the WHO for the INN abimufloxacin (proposed INN list 135, Jul 2026).
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 7-(6-amino-5-cyanopyridin-3-yl)-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylic acid |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 14139 | abimufloxacin |
Synonyms ![]() |
| OPS-2071 |
Database Links ![]() |
|
| Specialist databases | |
Antibiotic DB
|
OPS-2071 |
| Other databases | |
| CAS Registry No. | 1426216-93-4 (source: Scifinder) |
| GtoPdb PubChem SID | 491299979 |
| PubChem CID | 71289877 |
| Search Google for chemical match using the InChIKey | DTSKYQBTFHFYAZ-UHFFFAOYSA-N |
| Search Google for chemicals with the same backbone | DTSKYQBTFHFYAZ |
| Search PubMed clinical trials | abimufloxacin |
| Search PubMed titles | abimufloxacin |
| Search PubMed titles/abstracts | abimufloxacin |
| UniChem Compound Search for chemical match using the InChIKey | DTSKYQBTFHFYAZ-UHFFFAOYSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | DTSKYQBTFHFYAZ-UHFFFAOYSA-N |